FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 29, 2017, Fennec Pharmaceuticals Inc.’s (“Fennec”) Board of Directors adopted amendments to Fennec’s Amended and Restated Stock Option Plan (as amended, the “Plan”). The amendments include:

· limiting eligible participants under the Plan to individuals (as opposed to entities); and
· changing prior references in the Plan from the American Stock Exchange to the NASDAQ Stock Market (“NASDAQ”) consistent with the September 13, 2017 listing of Fennec’s common stock on NASDAQ.

A complete copy of the Plan is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The foregoing description of the Plan is qualified in its entirety by reference to the complete text of the Plan.

Item 9.01 Financial Statements and Exhibits.


FENNEC PHARMACEUTICALS INC. Exhibit
EX-10.1 2 v476228_ex10-1.htm EXHIBIT 10.1   Exhibit 10.1   FENNEC PHARMACEUTICALS INC. AMENDED AND RESTATED STOCK OPTION PLAN as amended on September 29,…
To view the full exhibit click here

About FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF)

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.